Pharmaceuticals, Biotechnology and Life Sciences
Treatment emergent adverse events Grade 3 or higher were reported by 20 of 32 patients from the 50/60 dose pooled patient analysis; no patient reported Grade 3 or higher fatigue or peripheral neuropathy (primary endpoint) –
FDA has approved Ipsen’s new pre-filled syringe for Somatuline
Depot.
Ipsen Q1 2019 sales growth of 17.0% as reported, or 15.8%1at constant exchange rates and consolidation scope.
Ipsen has presented results of Dysport and botulinum toxins pipeline, from basic science to clinical phases, and patients and caregivers surveys, highlighting differentiation of Dysport in the treatment of spasticity and movement disorders.
Ipsen and Exelixis on Tuesday said that their phase 3 study of study of cabozantinib in patients with advanced liver…
David Meek, Chief Executive Officer of Ipsen, said that the company’s performance in the first half of 2017 exceeded expectations, leading to an improved financial outlook for the full year.
Ipsen’s partner Teijin Group healtcare’s Pharma Limited, has received approval from the Japanese Ministry of Health, Labour and Welfare for Ipsen’s subcutaneous drug Somatuline (lanreotide) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP NET).
Ipsen has completed acquisition of a portfolio of five consumer healthcare products from Sanofi.
Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK, in coordination with fourteen other European regulatory agencies, has approved a new indication for Ipsen’s Decapeptyl as adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine-responsive early-stage breast cancer in women at high-risk of recurrence who are confirmed as pre-menopausal after completion of chemotherapy.
Ipsen has entered into a definitive agreement to acquire Sanofi’s five consumer healthcare products in certain European territories.